Here are 1-2 brief analogies for CytoSorbents (CTSO):

1. Think of them as a specialized **Fresenius Medical Care**, but for purifying blood from a broader range of toxins and inflammatory substances in critical care, beyond just kidney dialysis.
2. Like **Baxter International**, but singularly focused on advanced blood purification and filtration systems for treating critical illnesses such as sepsis and surgical complications.

• CytoSorb: An extracorporeal cytokine filter used for adjunctive therapy in sepsis, other critical care applications, cardiopulmonary bypass, and organ transplant.
• VetResQ: A device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
• CytoSorb-XL: A device designed for adjunctive therapy in the treatment of sepsis and other critical illnesses.
• HemoDefend: A blood purification technology platform aimed at reducing contaminants in the blood supply and removing blood group antibodies.
• K+ontrol: A device intended for the treatment of severe hyperkalemia in patients with life-threatening conditions.
• ContrastSorb: A device for the removal of IV contrast from blood during imaging procedures to mitigate the risk of contrast-induced nephropathy.
• BetaSorb: A device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure.
• DrugSorb: A device developed to remove toxic chemicals from the blood.
• DrugSorb-ATR: An antithrombotic removal system designed to remove antithrombotic agents from the blood.

CytoSorbents (CTSO) develops and commercializes medical devices, primarily their blood purification technology platform. Based on the product descriptions, the company sells primarily to institutions within the healthcare sector, rather than directly to individuals. Therefore, its major customers fall into the following categories:

1. Hospitals and Critical Care Units: These facilities utilize CytoSorb for adjunctive therapy in the treatment of sepsis, other critical care applications, and the prevention and treatment of perioperative complications of cardiopulmonary bypass surgery.

2. Organ Transplant Centers: These centers use CytoSorb for maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.

3. Veterinary Clinics and Hospitals: These facilities are customers for VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

4. Blood Banks and Transfusion Centers: These institutions could be customers for technologies like HemoDefend, which aims to reduce contaminants in the blood supply.

Dr. Phillip P. Chan, MD, PhD Chief Executive Officer and Director

Dr. Chan has led CytoSorbents for over 16 years, guiding the company through EU approval and commercialization of its flagship product, CytoSorb. Prior to CytoSorbents, he was a Partner at the $80M NJTC Venture Fund, leading healthcare and life science investments. He is also a co-founder and Vice Chairman of Medality Medical (formerly Andrew Technologies), a privately-held medical device company. Additionally, Dr. Chan founded CytoSorbents Europe GmbH in 2012.

Peter J. Mariani Chief Financial Officer and Principal Accounting Officer

Prior to joining CytoSorbents, Mr. Mariani served as Chief Financial Officer at Hansen Medical, Inc., a publicly traded medical robotics company. He also held senior financial positions, including Vice President of Finance and Administration and Corporate Vice President, Controller and Chief Accounting Officer, during his 12 years with Guidant Corporation, a global leader in medical devices for cardiovascular disease.

Vincent J. Capponi, MS President and Chief Operating Officer

Mr. Capponi brings over 20 years of management experience in medical devices, pharmaceuticals, and imaging equipment from companies such as Upjohn, Sims Deltec, and Sabratek. He joined CytoSorbents in 2002 as VP of Operations, was promoted to Chief Operating Officer in 2005, and became President in 2020. He was instrumental in scaling up the company's polymer technology and securing EU CE Mark designation for CytoSorb.

Dr. Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI Chief Medical Officer

Dr. Deliargyris is triple board-certified in internal medicine, cardiology, and interventional cardiology. Before joining CytoSorbents in 2020, he served as CMO for PLX Pharma (NASDAQ: PLXP) and as Global Medical Lead at The Medicines Company (NASDAQ: MDCO), where he led the FDA and EMA approval of Cangrelor. His prior experience also includes roles as Director of Cardiology and Interventional Cardiology at Athens Medical Center and Assistant Professor at Wake Forest University Medical Center.

Dr. Irina Kulinets, PhD Senior Vice President of Global Regulatory Affairs

Dr. Kulinets joined CytoSorbents in January 2023, bringing over 30 years of experience in regulatory affairs and clinical research for medical devices, biologics, and combination products. She previously served as the SVP of Regulatory Affairs, Clinical Research, and Quality at MicroVention, Inc., a division of Terumo Corporation. Her extensive background includes working for major life science corporations like Johnson & Johnson and Boston Scientific, and serving as a third-party FDA Inspector and 510(k) reviewer.

The key risks to CytoSorbents' business are primarily centered around regulatory hurdles, financial sustainability, and market reliance on its flagship product.

1. Regulatory Approval and Market Access Challenges in North America

A significant risk for CytoSorbents is its ongoing struggle to gain regulatory approval and broad market access for its devices, particularly in the United States and Canada. While its flagship product, CytoSorb, is approved in the European Union and distributed in over 70 countries, it has not yet received general approval for use in the U.S. beyond an Emergency Use Authorization for COVID-19 patients. The company's DrugSorb-ATR device, designed to reduce perioperative bleeding, has encountered regulatory rejections from both the U.S. FDA and Health Canada, citing a need for additional information and non-compliance with certain regulations. This situation severely limits the company's ability to penetrate the substantial U.S. hospital market, which is considered a major weakness, and contributes to slow and costly clinical trial progress for its core indications. The successful obtainment of U.S. FDA and Health Canada marketing authorization or approval is a critical factor influencing the company's future financial results.

2. High Revenue Concentration on CytoSorb and Persistent Net Losses

CytoSorbents faces a substantial risk due to its heavy reliance on CytoSorb for its revenue stream. This product concentration means that any unforeseen regulatory changes, increased competition, or supply chain disruptions impacting CytoSorb's markets, particularly in Europe, could significantly and immediately affect the company's top-line revenue. Furthermore, the company has a history of persistent net losses and is in a capital-intensive growth phase, necessitating continuous capital raises to fund its operations. As of November 2025, CytoSorbents reported an earnings before interest and tax (EBIT) loss of US$16 million, and by January 2026, it was noted as quickly burning through cash with negative EBITDA of $12.7 million over the preceding twelve months. Although the company has implemented a strategic workforce and cost reduction plan with the aim of reaching operating cash flow break-even in the first quarter of 2026, the ongoing losses and dependence on a single product outside major markets represent a significant financial vulnerability.

3. Competition

CytoSorbents operates in a competitive landscape within the medical device industry, facing challenges from larger medtech firms. Competition is consistently cited as a factor that could cause the company's actual results to differ materially from its forward-looking statements. This risk is amplified by CytoSorbents' existing challenges in securing broad regulatory approvals and market access in key regions like North America, making it harder to compete effectively against more established players with greater resources and market penetration.

CytoSorbents Corporation (NASDAQ: CTSO) operates in several medical device markets utilizing its blood purification technology. The addressable markets for its main products and services are detailed below:

CytoSorb (for Sepsis, Critical Care, Cardiopulmonary Bypass Surgery, and Organ Transplant)

• CytoSorbents estimates the total addressable market for numerous critical care and cardiac surgery applications with CytoSorb to be in excess of $30 billion worldwide.
• The global sepsis therapeutics market was estimated at approximately USD 3.95 billion in 2024 and is projected to reach approximately USD 5.65 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2030. Other estimates for the global sepsis therapeutics market include USD 3.72 billion in 2024, projected to reach USD 7.36 billion by 2034 (CAGR of 7.06% from 2025 to 2034). North America held the largest share of the global sepsis therapeutics market in 2024.
• The global blood purification devices market was valued at approximately USD 17.73 billion in 2024 and is expected to reach approximately USD 26.86 billion by 2032, with a CAGR of 5.40% during the forecast period. The global blood purification equipment market was valued at approximately USD 22.2 billion in 2024 and is projected to reach approximately USD 36.7 billion by 2033, exhibiting a CAGR of 5.76% from 2025 to 2033.
• The global cardiopulmonary bypass machine market was valued at approximately USD 274.09 million in 2024 and is anticipated to reach approximately USD 389.79 million by 2032, expanding at a CAGR of 4.5% between 2025 and 2032. North America held the largest market share in 2024.
• The global organ care products market size is projected to be worth around USD 757.90 million by 2034, growing from approximately USD 174.19 million in 2024 at a CAGR of 15.84% from 2025 to 2034. North America dominated the global organ care products market with the largest market share of 56% in 2024.

K+ontrol (for treatment of severe hyperkalemia)

• The global hyperkalemia treatment market is projected to reach nearly USD 2.0 billion by 2030, with a market value of approximately USD 1.34 billion in 2024, growing at a CAGR of 6.8%.
• The global hyperkalemia drugs market size was estimated at approximately USD 1.23 billion in 2024 and is projected to reach approximately USD 3.87 billion by 2033, growing at a CAGR of 13.8% from 2025 to 2033. North America accounted for approximately 45% of the global market share for hyperkalemia treatments.

ContrastSorb (for the removal of IV contrast in blood to reduce the risk of contrast-induced nephropathy)

• The global Contrast-Induced Nephropathy (CIN) Market was valued at approximately USD 1.2 billion in 2024 and is projected to reach approximately USD 2.5 billion by 2034, expanding at a CAGR of 8.5% during 2025-2034. North America was the largest market for CIN in 2024.

DrugSorb-ATR (antithrombotic removal system for cardiac surgery)

• While a specific addressable market size for DrugSorb-ATR alone was not identified, this product targets mitigating bleeding risks during coronary artery bypass graft (CABG) surgery for patients on antithrombotic drugs. It aims to reduce bleeding complications in patients on blood thinners undergoing cardiac surgery. This aligns with the cardiopulmonary bypass market mentioned above.

BetaSorb (for chronic renal failure)

• While a specific market size for BetaSorb was not found, it addresses health complications from metabolic toxins in patients with chronic renal failure. The renal diseases segment led the blood purification equipment market in 2024. The global acute kidney injury treatment sector is projected to reach a valuation of USD 5.7 billion by 2036, accelerating from USD 2.7 billion in 2026 at a CAGR of 7.6%.

CytoSorbents (CTSO) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Continued growth of the core CytoSorb business in international markets: The company has demonstrated strong sales in its distributor territories and other direct markets outside Germany, with Q3 2025 revenue increasing 10% year-over-year and trailing twelve-month core product sales reaching $37 million. Efforts to revitalize the direct German market, where a reorganization of the commercial team is underway, are anticipated to lead to improved performance and execution in 2026, further contributing to the growth of the core business.
2. Commercialization and market penetration of DrugSorb-ATR in North America: A significant driver is the anticipated regulatory approval and subsequent launch of DrugSorb-ATR in the United States and Canada. CytoSorbents expects a regulatory decision from the FDA for DrugSorb-ATR in mid-2026, following a planned De Novo application in Q1 2026. The positive results from the pivotal STAR-T study for DrugSorb-ATR, which focuses on reducing perioperative bleeding in cardiac surgery patients, support this launch into what the company views as a significant market opportunity.
3. Expanding applications and increased utilization of CytoSorb: The continuous accumulation of clinical data and the growing number of CytoSorb treatments worldwide, surpassing 300,000, are expected to further drive adoption and utilization in its approved indications across 76 countries. The existing CE mark extensions for applications such as bilirubin and myoglobin removal, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery, suggest potential for broader use of the device.

Share Repurchases

No significant share repurchase programs or dollar amounts of repurchases made or authorized were found for CytoSorbents (CTSO) in the last 3-5 years.

Share Issuance

• CytoSorbents conducted a Rights Offering in December 2024, which closed in Q1 2025, raising $6.8 million net of fees and releasing $5.0 million of restricted cash, increasing liquidity by $11.8 million.
• The Rights Offering allowed investors to purchase a maximum of 6.25 million units, with an additional 6.25 million common shares reserved for the exercise of short-term Right Warrants, for a total potential issuance of 12.5 million shares.
• As part of an amended credit agreement in November 2025, the company issued warrants to Avenue Capital Group to purchase 1,428,571 shares of common stock at an exercise price of $0.70.

Inbound Investments

• In November 2025, CytoSorbents amended its credit agreement with Avenue Capital Group, which provided an immediate additional $2.5 million in cash and extended the interest-only period through December 31, 2026.
• The amended agreement also provides for an additional $2.5 million if DrugSorb-ATR receives FDA marketing approval, which would further extend the interest-only period to June 30, 2027.

Outbound Investments

No specific strategic investments in other companies were reported for CytoSorbents (CTSO) in the last 3-5 years.

Capital Expenditures

• Net cash used in investing activities was approximately $0.124 million for the third quarter of 2025, compared to approximately $0.545 million for the third quarter of 2024.
• The company's focus includes advancing its DrugSorb-ATR device for North American market authorization and expanding its global footprint, such as opening a new regional sales subsidiary in Dubai, UAE, to access the Middle East and Africa markets.
• Cost-cutting measures implemented in 2025, including reductions in headcount and termination of non-core R&D programs, are aimed at reducing cash burn and achieving operating cash flow breakeven.